RSS Feeds
Tolerability of Rofecoxib versus Naproxen
- Jeffrey R. Lisse, MD;
- Monica Perlman, MD, MPH;
- Adam B. Polis, MA; and
- Gregory P. Geba, MD, MPH
- From University of Arizona, Tuscon, AZ 85711; Scripps Clinic and Research Foundation, San Diego, CA 92037; and Merck & Co., Inc., West Point, PA 19486, and Richboro, PA 19486.
The Editors welcome submissions for possible publication in the Letters section. Authors of letters should:
•Include no more than 300 words of text, three authors, and five references
•Type with double-spacing
•Send three copies of the letter, an authors' form signed by all authors, and a cover letter describing any conflicts of interest related to the contents of the letter.
Letters commenting on an Annals article will be considered if they are received within 6 weeks of the time the article was published. Only some of the letters received can be published. Published letters are edited and may be shortened; tables and figures are included only selectively. Authors will be notified that the letter has been received. If the letter is selected for publication, the author will be notified about 3 weeks before the publication date. Unpublished letters cannot be returned.
Annals welcomes electronically submitted letters.
IN RESPONSE:
It is important to understand differences between dual cyclooxygenase-inhibiting NSAIDs and coxibs …
